Neha Motwani Elected to Longeveron® Board of Directors
July 09 2024 - 9:00AM
Longeveron Inc. (NASDAQ: LGVN), a clinical stage regenerative
medicine biotechnology company developing cellular therapies for
life-threatening and chronic aging-related conditions, including
hypoplastic left heart syndrome (HLHS) and Alzheimer’s disease,
today announced that Neha Motwani, a senior healthcare investment
banker, has been elected to the Longeveron Board of Directors at
the Company’s recent Annual Meeting of Stockholders.
“I am delighted to welcome Neha, with her
tremendous healthcare industry experience, to the Board of
Directors,” said Joshua Hare, Co-founder, Chief Science Officer and
Chairman of the Board at Longeveron. “Her extensive knowledge of
biopharma company operations, financing and capital markets will
bring significant value to Longeveron as we continue to advance
Lomecel-B™, our proprietary, scalable, allogeneic cellular therapy.
With five positive clinical trials across three indications, we
believe Lomecel-B™ has the potential to be an important
therapy for some of the most difficult diseases and conditions
associated with aging.”
Neha Motwani has over 25 years of healthcare
investment banking experience, most recently serving as Managing
Director, Healthcare Investment Banking at William Blair. She
previously held investment banking roles of increasing
responsibility with Truist Securities, Oppenheimer and Company,
Stifel Financial and Cowen and Company, where, collectively, she
completed transactions raising approximately $7.0 billion. Ms.
Motwani earned her B.A. in political science from Columbia
University.
“I am delighted to join the Board of Directors
of Longeveron at this exciting phase of the Company’s clinical
development,” said Ms. Motwani. “I look forward to working with
this talented team to continue their mission to advance their novel
cellular therapy, Lomecel-B™ for the potential treatment of
HLHS, a rare and devastating congenital heart condition, and
diseases of the aging.”
About Longeveron Inc.
Longeveron is a clinical stage biotechnology
company developing regenerative medicines to address unmet medical
needs. The Company’s lead investigational product is Lomecel-B™, an
allogeneic medicinal signaling cell (MSC) therapy product isolated
from the bone marrow of young, healthy adult donors. Lomecel-B™ has
multiple potential mechanisms of action encompassing pro-vascular,
pro-regenerative, anti-inflammatory, and tissue repair and healing
effects with broad potential applications across a spectrum of
disease areas. Longeveron is currently pursuing three pipeline
indications: hypoplastic left heart syndrome (HLHS), Alzheimer’s
disease, and Aging-related Frailty. The Lomecel-B™ HLHS
program has received three distinct and important FDA designations:
Orphan Drug designation, Fast Track designation, and Rare Pediatric
Disease designation. For more information, visit www.longeveron.com
or follow Longeveron on LinkedIn, X, and Instagram.
Investor Contact:Derek ColeInvestor Relations
Advisory Solutionsderek.cole@iradvisory.com
A photo accompanying this announcement is available at
https://www.globenewswire.com/NewsRoom/AttachmentNg/00f0eb5c-76f5-49b1-9994-ee363513547b
Longeveron (NASDAQ:LGVN)
Historical Stock Chart
From Oct 2024 to Nov 2024
Longeveron (NASDAQ:LGVN)
Historical Stock Chart
From Nov 2023 to Nov 2024